Biotechnology company TC BioPharm (Holdings) plc (TCBP) announced Monday the execution of a non-binding letter of intent to acquire a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies for the treatment of refractory cancers and solid tumors.This agreement is the second such agreement in as many months that shows TC BioPharm's commitment to its M&A strategy aimed at expanding its therapeutic platform.

生物技术公司TC BioPharm（Holdings）plc（TCBP）周一宣布签署一份不具约束力的意向书，以收购一家私营生物技术公司，该公司致力于开发创新的嵌合抗原受体T细胞（CAR-T）疗法，用于治疗难治性癌症和实体瘤。该协议是数月来第二份此类协议，表明TC BioPharm致力于其旨在扩大其治疗平台的并购战略。

CAR T-cell therapy modifies a patient's own immune cells to provide a heightened ability to identify and eliminate cancer cells. .

CAR T细胞疗法可以改变患者自身的免疫细胞，从而提高识别和消除癌细胞的能力。

The target acquisition has developed a number of proprietary approaches to re-engineer CARs to better target solid tumors. The Company has generated pre-clinical proof of concept data that demonstrates the therapeutic potential of its lead CAR-T candidate for a range of solid tumors including colorectal, pancreatic, mesothelioma, ovarian and breast cancerIn addition, the target acquisition is also developing a novel, allogeneic CAR-T for the treatment of autoimmune diseases.

target收购开发了许多专有方法来重新设计CAR以更好地靶向实体瘤。该公司已经产生了临床前概念验证数据，证明了其主要CAR-T候选物对包括结直肠癌，胰腺癌，间皮瘤，卵巢癌和乳腺癌在内的一系列实体瘤的治疗潜力。此外，target收购公司还正在开发一种新的异基因CAR-T，用于治疗自身免疫性疾病。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。